Navigation Links
NxStage Reports Record Second Quarter 2014 Financial Results And Increases Full-Year Revenue Guidance

LAWRENCE, Mass., Aug. 7, 2014 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported second quarter revenue that exceeds the top end of its guidance range.

Revenue for the second quarter of 2014 increased 13 percent to a record $74.1 million, compared with revenue of $65.5 million for the second quarter of 2013, and exceeded the Company's guidance range for the second quarter. The increase in revenue was driven by strong adoption of the NxStage® System OneTM hemodialysis machine within the Home, both within US and international markets, and the Critical Care market.

Home revenue increased 18 percent to $38.5 million for the second quarter of 2014 compared with revenue of $32.7 million for the second quarter of 2013. 

Critical Care revenue increased 15 percent to $12.4 million for the second quarter of 2014 compared with revenue of $10.8 million for the second quarter of 2013.

In-center revenue was $21.0 million for the second quarter of 2014 compared with revenue of $21.2 million for the second quarter of 2013.

NxStage reported a net loss of $7.1 million, or $(0.12) per share for the second quarter of 2014 compared with a net loss of $3.4 million, or $(0.06) per share for the second quarter of 2013. Consistent with the Company's expectations, net loss for the second quarter of 2014 included $3.2 million in losses associated with the Company's market development activities with NxStage Kidney Care, which is designed to support the adoption of home hemodialysis.

"We are very pleased with our performance throughout the first half of the year which reflects continuing momentum with our strategic growth initiatives," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage. "Home is tracking ahead of plan with second quarter revenue up 18%, representing the best year over year growth in Home since Q4 of 2011.  Consistent with our plans, we are accelerating adoption of home hemodialysis with the System One and building a long-term sustainable growth path for NxStage. Based on our strong start to the year, as well as our increased confidence in the second half, we believe we are well positioned to top our 15% annual Home revenue growth target and exceed our previous guidance for total revenue."


The Company now expects full-year revenue for 2014 to be between $290 and $293 million, versus its previous guidance of $283 to $288 million. The Company's full-year net loss guidance remains unchanged at $23 to $27 million.

For the third quarter of 2014, the Company expects revenue to be in a range of $71.0 and $72.5 million, and a net loss in the range of $7.5 to $8.5 million.

Conference Call:NxStage will also host a conference call today, Thursday, August 7, 2014 at 9:00 a.m. Eastern Time to discuss its second quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international). The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at

A replay of the conference call will be available two hours after the completion of the call through August 15, 2014. To access the replay, dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 75983589. An online archive of the conference call can be accessed via the investor relations section of the Company's website at

About the NxStage System OneThe NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the FDA. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow™ SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation, and at a medically appropriate treatment frequency.

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products domestically and internationally, growth in home and/or more frequent hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and more frequent hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, including in response to the Company's NxStage Kidney Care initiative, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

 Contact:Kristen K. Sheppard, Esq.VP, Investor 

 NxStage Medical, Inc.Condensed Consolidated Statements of Comprehensive Loss(in thousands, except per share data)(unaudited)Three Months Ended
June 30,Six Months Ended
June  30,2014201320142013Revenues





127,106Cost of revenues

46,55340,37589,84078,019Gross profit

27,53025,08756,46449,087Operating expenses:Selling and marketing

13,58911,71626,80722,412Research and development


6,4855,03713,0359,945General and administrative

8,3998,23917,22016,063Total operating expenses

34,18129,35867,90457,894Loss from operations

(6,651)(4,271)(11,440)(8,807)Other expense:Interest expense

(195)(150)(393)(300)Other (expense) income, net

(17)(10)6(186)(212)(160)(387)(486)Net loss before income taxes

(6,863)(4,431)(11,827)(9,293)Provision for (benefit from) income taxes

332(1,026)678(894)Net loss

(7,195)(3,405)(12,505)(8,399)Less: Net loss attributable to noncontrolling interests

(82)(117)Net loss attributable to stockholders of NxStage Medical,




(12,388)(8,399)Net loss per share, basic and diluted





(0.14)Weighted-average shares outstanding, basic and diluted

61,46960,03661,48459,706Other comprehensive income (loss)

173(704)355(559)Total comprehensive loss

(7,022)(4,109)(12,150)(8,958)Less: Comprehensive loss attributable to noncontrolling

(82)(117)Total comprehensive loss attributable to stockholders of
NxStage Medical, Inc.





(8,958) NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited)June 30,December 31,20142013ASSETSCurrent assets:Cash and cash equivalents



84,134Accounts receivable, net


43,35037,801Prepaid expenses and other current assets

4,5374,027Total current assets

141,052146,120Property and equipment, net

60,62952,478Field equipment, net

17,80813,041Deferred cost of revenues

33,09734,730Intangible assets, net


41,81741,817Other assets

2,5731,582Total assets



306,962LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable



14,610Accrued expenses

21,19521,025Current portion of long-term debt

103102Other current liabilities

1,8701,870Total current liabilities

45,69337,607Deferred revenues

51,83153,277Long-term debt

1,0041,044Other long-term liabilities

24,03020,273Total liabilities

122,558112,201Commitments and contingenciesStockholders' equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized;
  no shares issued and outstanding as of June 30, 2014 and December 31, 2013

Common stock: par value $0.001, 100,000,000 shares authorized; 62,185,421 and
61,666,048 shares issued as of June 30, 2014 and December 31, 2013, respectively

6261Additional paid-in capital

575,123567,468Accumulated deficit

(375,930)(363,542)Accumulated other comprehensive income

567212Treasury stock, at cost: 579,121 and 575,895 shares as of June 30, 2014 and December
31, 2013, respectively

(10,010)(9,963)Total NxStage Medical, Inc. stockholders' equity

189,812194,236Noncontrolling interest

408525Total stockholders' equity

190,220194,761Total liabilities and stockholders' equity



306,962 NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited)Six Months Ended June 30,20142013Cash flows from operating activities:Net loss



(8,399)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

13,34312,259Stock-based compensation


4501,226Changes in operating assets and liabilities:Accounts receivable


(17,523)(12,067)Prepaid expenses and other assets

(550)(2,584)Accounts payable

7,9481,955Accrued expenses and other liabilities

1,206(1,270)Deferred revenues

(1,395)(4,439)Net cash used in operating activities



(9,737) NxStage Medical, Inc.Revenues by Segment(in thousands)(unaudited)Three Months Ended
June 30,Six Months Ended
June 30,2014201320142013System One segmentHome





64,130Critical Care

12,42210,82627,11421,536Total System One segment

50,91043,497102,09785,666In-Center segment


1,9437273,9971,502Products subtotal

73,85665,462146,013127,106Services segment

428544Elimination of intersegment revenues








Logo -

SOURCE NxStage Medical, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
2. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
3. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
4. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
5. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
7. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
8. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
9. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
10. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 /PRNewswire/ ... --> Juntendo universitetssjukhus ser potential att ... av magnetresonansbilder (MR-bilder) för patienter med ... tecknat ett forskningsavtal med SyntheticMR AB för ... kliniska forskningsprojekt på sjukhuset. Med SyMRI kan ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical ... professionals and offered by healthcare staffing agency Aureus Medical Group . ... of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... second medical opinion process, participated in the 61st annual Employee Benefits Conference. The ... and took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
Breaking Medicine News(10 mins):